Synonyms: LGK-974 | WNT-974 | WNT974
Compound class:
Synthetic organic
Comment: LGK974 is a clinical stage porcupine inhibitor [2]. It is being developed as an oncology therapeutic [1]. It is the first porcupine inhibitor to advance to clinical trial.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Li J, Wu G, Xu Y, Li J, Ruan N, Chen Y, Zhang Q, Xia Q. (2020)
Porcupine Inhibitor LGK974 Downregulates the Wnt Signaling Pathway and Inhibits Clear Cell Renal Cell Carcinoma. Biomed Res Int, 2020: 2527643. DOI: 10.1155/2020/2527643 [PMID:32104684] |
2. Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T, Kasibhatla S, Schuller AG, Li AG, Cheng D et al.. (2013)
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci USA, 110 (50): 20224-9. [PMID:24277854] |